By Bobby Jindal & Newt Gingrich
Recent weeks have brought something rare to Washington: meaningful, bipartisan progress on health care costs—progress built on a simple idea that should extend across the entire system.
Congress included significant pharmacy benefit manager (PBM) reforms in the 2026 spending package that strengthened transparency and rebate pass-through requirements—policies that shift financial incentives from industry middleman toward patient care.
The Trump Department of Justice quickly reinforced this direction, with the Trump administration securing a high-profile settlement with Express Scripts that targeted secret pricing practices and misaligned incentives. At the same time, the Trump Department of Labor (DOL) has proposed new rules to expand disclosure of PBM compensation and potential conflicts of interest, giving employer health plans clearer oversight tools. Market-driven innovations such as TrumpRx have demonstrated the benefits of transparent drug pricing made available directly to consumers.